The present invention relates to a dermal layer which is for grafting and has an improved graft survival rate, and a method for producing the same, wherein the dermal layer for grafting can be produced by filling a filling solution, including a DNA fragment mixture and chitosan, into an acellular dermal matrix from which cells have been removed. It was observed that the dermal layer for grafting produced in this manner, due to the filling solution filled therein and including a DNA fragment mixture and chitosan, increases the rate at which cells flow in from the tissue surrounding the graft and are fixed, and thereby alleviates an initial inflammatory reaction and promotes blending with the surrounding tissue.

Systems, methods, and compositions for cryopreservation and reconstitution of engineered tissues. The engineered tissue compositions are functional after a cryopreservation-thaw cycle For example, the tissue compositions retain their structural integrity, maintain cell-cell communication, etc. In certain embodiments, the tissue compositions exhibit synchronous contractions, secrete a hormone, secrete a cytokine, secrete an RNA, secrete a growth factor, secrete an enzyme, and/or secrete a neurotransmitter, etc. in some embodiments, engineered tissue compositions are cultured, cryopreserved, and reconstituted in a closed system.

Volumetric muscle loss (VML) injuries characterized by critical loss of skeletal muscle tissues result in severe functional impairment. Current treatments involving use of muscle grafts are limited by tissue availability and donor site morbidity. The present application relates to methods and composition matters for skeletal muscle healing and regeneration for a patient with volumetric muscle loss using a glycosaminoglycan-based hydrogel, wherein said hydrogel for skeletal muscle regeneration comprises functionalized hyaluronic acid (HA), functionalized chondroitin sulfate (CS) and poly(ethylene glycol) diacrylate (PEGDA), wherein said HA and said CS are cross-linked by said PEGDA.

Described are embodiments of a multilaminate or multiple layer implantable surgical graft comprising remodelable collagenous sheet material, the graft including one or more interweaving members to stitch together the graft to help prevent the layers from delaminating or separating during handling and the initial stages of remodeling. The interweaving members may comprise lines of suture, thread, individual stitches, strips of material, etc. that are woven through the layers of biomaterial in a desired pattern. In one embodiment, the interweaving members comprise a pharmacologically active substance, such as a drug, growth factors, etc. to elicit a desired biological response in the host tissue. In another embodiment, the graft further comprises a reinforcing material, such as a synthetic mesh, within the layers of remodelable biomaterial and stitched together by one or more interweaving members.

The present disclosure provides compositions and methods for regenerating airway stem cells, as well as methods for treating an airway disease (e.g., cystic fibrosis (CF)) in a subject using the regenerated airway stem cells.

Described herein are bioengineered constructs and methods of producing the same. The constructs and methods disclosed herein can be applied towards, for example, the generation of vascular grafts to treat cardiovascular disease.

Methods and devices are disclosed for processing stromal precursor cells (i.e., cells which can differentiate into connective tissue cells, such as in muscles, ligaments, or tendons) which can be obtained from fatty tissue extracts obtained via liposuction. Normal processing of a liposuction extract involves centrifugation, to concentrate the stromal cells into a semi-concentrated form called “spun fat”. That “spun fat” can then be treated by mechanical processing (such as pressure-driven extrusion through 0.5 mm holes) under conditions which can gently pry the stromal cells away from extra-cellular collagen fibers and other debris in the “spun fat”. The extruded mixture is then centrifuged again, to separate a highly-enriched population of stromal cells which is suited for injection back into the patient (along with platelet cells, if desired, to further promote tissue repair or regeneration).

Compositions and methods for their manufacture and use are provided comprising a soluble extracellular matrix fraction for intravascular delivery which forms a gel or coating in situ for treatment of myocardial infarction and ischemia in a variety of tissues and endothelial injury/dysfunction.

The present invention relates to novel compositions and methods for reducing or eliminating the thrombogenicity of a graft by modifying the graft with a cell-derived extracellular matrix lacking thrombospondin-2 (TSP2-null ECM) to render it non-thrombogenic when transplanted to a subject in need thereof. The invention also provides a method for improving the biocompatibility of a medical device or an implant by modifying the medical device or implant with a cell-derived TSP2-null ECM, whereby the medical device or implant is rendered non-thrombogenic and pro-migratory.

This disclosure describes decellularized, biologically-engineered tubular grafts and methods of making and using such decellularized, biologically-engineered tubular grafts.